Literature DB >> 22752646

DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia.

Nina Erčulj1, Barbara Faganel Kotnik, Maruša Debeljak, Janez Jazbec, Vita Dolžan.   

Abstract

PURPOSE: Patients treated for childhood acute lymphoblastic leukemia (ALL) are considered to be at increased risk of developing second neoplasm. The aim of our study was to identify DNA repair polymorphisms contributing to the risk of second neoplasm in clinically well-characterized Slovenian patients treated for childhood ALL.
METHODS: Pediatric patients diagnosed with ALL between 1971 and 2001 were included in the study. According to the identified clinical risk factors for second neoplasm, a matched set of cases with second neoplasm and controls was selected and genotyped for 11 DNA repair polymorphisms.
RESULTS: Among 359 pediatric patients with ALL, 20 second neoplasms were observed. The dose of radiotherapy (P = 0.011), administration of epipodophyllotoxins (P = 0.006), and the dose of anthracyclines (P < 0.001) showed a significant association with the risk of second neoplasm. Among genetic factors, we observed a significant association of NBN 1197G allele with increased risk of second neoplasms (RR = 4.36; 95 % CI: 1.19-15.98; P = 0.026), while the risk was decreased in carriers of XRCC3-316G allele compared with patients with wild-type genotype (RR = 0.20; 95 % CI: 0.04-0.99; P = 0.049).
CONCLUSIONS: Our results suggest an important role of NBN 1197A>G and XRCC3-316A>G polymorphisms in the development of second neoplasm in patients treated for childhood ALL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752646     DOI: 10.1007/s00432-012-1265-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  54 in total

Review 1.  Polymorphisms in DNA repair genes and associations with cancer risk.

Authors:  Ellen L Goode; Cornelia M Ulrich; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-12       Impact factor: 4.254

2.  siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status.

Authors:  Ken Ohnishi; Zorica Scuric; Robert H Schiestl; Noritomo Okamoto; Akihisa Takahashi; Takeo Ohnishi
Journal:  Radiat Res       Date:  2006-09       Impact factor: 2.841

3.  DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.

Authors:  Katja Ott; P Sivaramakrishna Rachakonda; Benjamin Panzram; Gisela Keller; Florian Lordick; Karen Becker; Rupert Langer; Markus Buechler; Kari Hemminki; Rajiv Kumar
Journal:  Ann Surg Oncol       Date:  2011-02-24       Impact factor: 5.344

4.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Authors:  Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

5.  Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.

Authors:  Martin Stanulla; Elke Schaeffeler; Anja Möricke; Sally A Coulthard; Gunnar Cario; André Schrauder; Peter Kaatsch; Michael Dördelmann; Karl Welte; Martin Zimmermann; Alfred Reiter; Michel Eichelbaum; Hansjörg Riehm; Martin Schrappe; Matthias Schwab
Journal:  Blood       Date:  2009-06-17       Impact factor: 22.113

6.  Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital.

Authors:  A W Walter; M L Hancock; C H Pui; M M Hudson; J S Ochs; G K Rivera; C B Pratt; J M Boyett; L E Kun
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

7.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

Authors:  A Reiter; M Schrappe; W D Ludwig; W Hiddemann; S Sauter; G Henze; M Zimmermann; F Lampert; W Havers; D Niethammer
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

8.  Second neoplasms after treatment of childhood cancer in Slovenia.

Authors:  Janez Jazbec; Patricija Ećimović; Berta Jereb
Journal:  Pediatr Blood Cancer       Date:  2004-06       Impact factor: 3.167

9.  Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study.

Authors:  J P Neglia; D L Friedman; Y Yasui; A C Mertens; S Hammond; M Stovall; S S Donaldson; A T Meadows; L L Robison
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 11.816

10.  PedGenie: an analysis approach for genetic association testing in extended pedigrees and genealogies of arbitrary size.

Authors:  Kristina Allen-Brady; Jathine Wong; Nicola J Camp
Journal:  BMC Bioinformatics       Date:  2006-04-18       Impact factor: 3.169

View more
  3 in total

1.  The contribution of XRCC3 genotypes to childhood acute lymphoblastic leukemia.

Authors:  Jen-Sheng Pei; Wen-Shin Chang; Pei-Chen Hsu; Chao-Chun Chen; Shun-Ping Cheng; Yun-Chi Wang; Chia-Wen Tsai; Te-Chun Shen; Da-Tian Bau
Journal:  Cancer Manag Res       Date:  2018-11-15       Impact factor: 3.989

2.  Ethnicity-stratified analysis of the association between XRCC3 Thr241Met polymorphism and leukemia: an updated meta-analysis.

Authors:  Zhengjun Xie; Wei Peng; Qiuhua Li; Wei Cheng; Xin Zhao
Journal:  BMC Med Genomics       Date:  2021-09-18       Impact factor: 3.063

3.  Human papillomavirus-associated subsequent malignancies among long-term survivors of pediatric and young adult cancers.

Authors:  Rohit P Ojha; Joseph E Tota; Tabatha N Offutt-Powell; James L Klosky; Timothy D Minniear; Bradford E Jackson; James G Gurney
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.